5 completed, 3 unknown, 2 recruiting, 1 not yet recruiting. 7 Phase 3, 3 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 4.
Follow CIN1: new trials by email Literature Review of CIN1 trials Research Report on CIN1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test Trichloroacetic acid - CIN1, Trichloroacetic Acid | Phase 2 / Phase 3 | Withdrawn | Department of Medical Services Ministry of Public Health of Thailand | 2023-11-30 | 2024-01-03 | |
| Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) Glizigen, Placebo - Papilloma Viral Infection, CIN1 | Phase 4 | Unknown | Catalysis SL | 120 | 2023-06-07 | 2024-02-07 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine HPV Infections, Cervical Cancer Stage IIa | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 600 | 2022-05-14 | 2024-04-17 | |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
| Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions ChAdOx1-HPV, MVA-HPV, Placebo - HPV Infection, CIN1 | Phase 1 / Phase 2 | Completed | Barinthus Biotherapeutics | 108 | 2021-03-16 | 2025-08-28 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent HPV Recombinant Vaccine, Placebo - Cervical Cancers, Vulvar Cancer | Phase 1 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 90 | 2018-10-10 | 2020-01-22 |
| Phase II Evaluation of AHCC for the Eradication of HPV Infections AHCC 3 grams once a day, Placebo - Human Papilloma Virus, Dysplasia | Not applicable | Completed | The University of Texas Health Science Center, Houston | 50 | 2015-04-01 | 2021-01-20 |
Uterine Cervical Neoplasms (9) · Condylomata Acuminata (8) · Papillomavirus Infections (7) · Vaginal Neoplasms (7) · Vulvar Neoplasms (5) · HIV Infections (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1)
Communicable Diseases (11) · DNA Virus Infections (11) · Disease Attributes (11) · Genital Diseases (11) · Infections (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Sexually Transmitted Diseases (11) · Sexually Transmitted Diseases, Viral (11) · Tumor Virus Infections (11) · Urogenital Diseases (11) · Virus Diseases (11) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases, Female (9)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Vaccines, Synthetic (2) · Acetic Acid (1) · Active Hexose Correlated Compound (1) · Trichloroacetic Acid (1)
Shanghai Bovax Biotechnology Co., Ltd. (8) · Barinthus Biotherapeutics (1) · Catalysis SL (1) · Department of Medical Services Ministry of Public Health of Thailand (1) · The University of Texas Health Science Center, Houston (1) · UNC Lineberger Comprehensive Cancer Center (1)
China (8) · Belgium (1) · Estonia (1) · Kenya (1) · Spain (1) · Thailand (1) · United Kingdom (1) · United States (1)
Chemtai Mungo, MD, MPH (1) · Jikai Zhang (1) · Judith A Smith, Pharm.D. (1) · Ting Huang (1)
R37CA306827 (1)